Anthem Biosciences Limited Q3 FY26 earnings call summary

Earnings call of 5 Feb 2026, summarised by AI from the filing.

Anthem Biosciences reported 9M FY26 revenue of ₹1,513 cr with 41.5% EBITDA margin, lowered FY26 revenue growth guidance to 15-16% while maintaining 20%+ EBITDA and PAT growth.

Key takeaways

1. FY26 guidance Revenue growth lowered to 15-16%; EBITDA and PAT growth guidance of 20%+ remains intact.
2. Margin improvement EBITDA margin improved to 41.5% from backward integration and material margin gains.
3. Growth drivers Peptides, biosimilars, and probiotics are key growth drivers; 4 new molecule approvals this year.
4. Destocking risk Customer destocking due to geopolitical uncertainty slowed growth; recovery signs emerging.

Original filing on BSE

Anthem Biosciences Limited Q1 FY27 results

As filed: Revenue ₹418 cr (−23% year on year), EBITDA ₹151 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 36.0% (+63 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹583 cr, EBITDA ₹267 cr, PAT ₹212 cr, EBITDA margin 45.8%. Not scored. No result for the same quarter last year. Share price after the results: +1.4% in 30 days (Nifty 500: +3.0%).
• Q3 FY26: Revenue ₹417 cr, EBITDA ₹163 cr, PAT ₹112 cr, EBITDA margin 39.1%. Not scored. No result for the same quarter last year. Share price after the results: +21.1% in 30 days (Nifty 500: +2.8%).
• Q2 FY26: Revenue ₹552 cr, EBITDA ₹225 cr, PAT ₹198 cr, EBITDA margin 40.8%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: 0.0%).
• Q1 FY26: Revenue ₹538 cr, EBITDA ₹196 cr, PAT ₹148 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year. Share price after the results: +10.4% in 30 days (Nifty 500: +2.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

Anthem Biosciences Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (22 Jul 2026), Results deck (21 Jul 2026), Results deck (21 Jul 2026), Results press release (21 Jul 2026), Results press release (21 Jul 2026)
• Q4 FY26: Earnings call (20 May 2026), Results deck (19 May 2026)
• Q3 FY26: Earnings call (5 Feb 2026), Results deck (5 Feb 2026), Results press release (5 Feb 2026), Results press release (5 Feb 2026), Results press release (5 Feb 2026)
• Q2 FY26: Earnings call (10 Nov 2025), Results deck (8 Nov 2025), Results press release (8 Nov 2025)
• Q1 FY26: Earnings call (14 Aug 2025), Results deck (13 Aug 2025), Results press release (13 Aug 2025)